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Open access under CC BY license.cis-Regulatory sequences (CRSs) direct cell-specific and
inducible gene expression in response to signal trans-
duction networks, and it is becoming apparent that
many cases of disease susceptibility and drug response
stratification are due to polymorphisms that alter CRS
responses in a context-dependentmanner. In the current
review, we describe successful methods for identifying
CRSs and analyzing the effects of allelic variation on
their responses to signal transduction. The technologies
described build on the successes of ENCODE (ENCyclo-
pedia Of DNA Elements) by exploring the effects of
polymorphisms on CRS context dependency. This un-
derstanding is essential to uncover the genomic basis of
disease susceptibility and will play a major role in deliv-
ering on the promise of personalized medicine.
Meta-analyses of multiple genome wide association (GWA)
(see Glossary) studies have shown that 88% of disease-
associated single nucleotide polymorphisms (SNPs) are
found within intronic or intergenic DNA [1,2], and GWA
studies designed to detect the causes of drug response
stratification [3] or unwanted side effects suggest a major
role for intronic and intergenic variations [4–8]. Although
many of these characteristics are associated with nonfunc-
tional SNPs, many of these sequence differences occur
within genomic regions of strong linkage disequilibrium
(LD) that contain functional SNPs, the majority of which
are noncoding [9]. Furthermore, a large proportion of GWA
study hits are found within gene deserts that contain no
genes, suggesting a role for long-distance gene regulation
in disease. By describing the human regulatory landscape
in unprecedented detail using many different cell culture
studies, the ENCODE (ENCyclopedia Of DNA Elements)
consortium have thrown down the gauntlet to biologists to
determine the regulatory causes of diseases [10–13]. The
next step in this process is to consider how polymorphic
variation within the cis-regulatory genome alters its activ-
ity in response to signal transduction cues that represent§ This is an open-access article distributed under the terms of the Creative Com-
mons Attribution License, which permits unrestricted use, distribution and reproduc-
tion in any medium, provided the original author and source are credited.
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mation from the cell surface to the genome (Figure 1).
This review examines current techniques for identifying
cis-regulatory sequences (CRSs) and describes methods
that allow characterization of their context-specific activi-
ties. We review methods for establishing the effects of
polymorphisms on the ability of CRSs to respond to signal
transduction pathways in specific cell types, and then
briefly summarize the possible influence of epigenetic
modification on these processes. Finally, we examine sev-
eral recent endeavors to investigate the effects on gene
regulation of noncoding SNPs, identified by GWA studies
of disease and drug nonresponse.
Classifying CRSs
The ENCODE consortium has very recently presented
evidence that 4.5 times more regulatory information is
present in the genome than information used to encode
proteins [10]. This observation shows that the amount of
functional biological information in the noncoding human
genome exceeds that of the coding genome, which is en-
tirely consistent with GWA analyses indicating that the
noncoding genome is an important reservoir of disease
causing or stratifying loci [1,2]. Many studies have sug-
gested that more than half of the most conserved regions of
the human genome consist of CRSs, which include promo-
ters, insulators, enhancers, and silencers that are essential
for the tissue-specific, temporal, and inducible expression
of genes (Figure 1) [14,15].
Promoter regions are orientation dependentwith respect
to the genes they control and consist of a ‘core’ sequence
bound by RNA polymerase II (RNApolII; Figure 1) and
secondary sequences required to support some level of
tissue-specific expression [16]. Twodifferent promoter types
have been characterized: large GC-rich, TATA-less promo-
ters, generally associated with constitutively expressed
genes, and smaller TATA box promoters that modulate
the expression of genes with high levels of tissue-specific
expression [10,16]. Using DNAse1 hypersensitivity map-
ping (Box 1), it has been shown that promoter regions
contain a nearly invariant 50-bp region occupied by the core
transcriptional apparatus (RNApolII and cofactors).
In contrast to promoters, enhancers and silencers are
largely orientation and, to some extent, distance indepen-
dent (Figure 1). Indeed, some enhancers, which upregulateed.2012.11.003 Trends in Molecular Medicine, February 2013, Vol. 19, No. 2 99
Glossary
Amygdala: a region of the brain that controls fear-related behavior and mood.
Misregulation of genes in this part of the brain may be involved in generating
mood disorders such as chronic anxiety and major depressive disorder.
Brain-derived neurotrophic factor (BDNF): a secreted protein that acts on
neurons of the central and peripheral nervous system; it supports the survival
of existing neurons, and encourages the growth and differentiation of new
neurons and synapses. Misregulation of BDNF expression has been linked to
mood disorders and obesity.
Cannabinoid receptor 1 gene (CNR1): encodes the cannabinoid 1 receptor CB1.
CB1 acts as the receptor for endogenous cannabinoids (anandemide) as well as
plant-derived cannabinoids. CB1 plays a role in appetite, inflammatory pain,
and modulating mood.
ChIP-seq: chromatin immunoprecipitation with next-generation sequencing
(Box 1).
Chromatin conformation capture carbon copy (5C): a method of detecting
long-range interaction between different sequences of the genome (Box 1).
cis-Regulatory genome: fraction of the human genome required to maintain
levels of cell-specific and inducible gene expression appropriate for health.
cis-Regulatory sequence (CRS): noncoding sequences that control the expres-
sion of genes within specific cells, at specific amounts, and in response to
specific stimuli. Include promoters, enhancers, silencers, and insulators.
Context dependent: cis-regulatory activity that is critically dependent on the
correct cell phenotype, cell interaction, signal transduction cue, or genomic
location.
DNAse1 hypersensitivity assay with next generation sequencing (DNAse-seq):
a genomic technique for detecting enhancers and promoter sequences (Box 1).
ENCODE consortium (ENCyclopedia Of DNA Elements consortium): an
international collaboration of research groups funded by the National Human
Genome Research Institute (NHGRI).
Enhancer: a sequence of DNA that interacts with activated transcription factors
and increases the activity of RNA polymerase II at a promoter region.
Formaldehyde-assisted identification of Regulatory elements and next gen-
eration sequencing (FAIRE-seq): a genomic technique for detecting enhancers
and promoter sequences (Box 1).
Galanin (GAL): a secreted neuropeptide implicated in many biologically diverse
functions, including inflammatory pain, cognition, feeding, and regulation of
mood.
Genome wide association (GWA) study: commonly an examination of many
thousands of common SNPs in thousands of different individuals to identify
alleles associated with disease susceptibility.
Hypothalamus: a region of the brain that controls several physiological
processes including appetite and thirst. Misregulation of genes in the
hypothalamus may explain many cases of obesity.
Insulator: a region of DNA that insulates the promoter of one gene from the
influences modulating the activity of a second gene promoter.
Intergenic: large areas of noncoding DNA between genes.
Linkage disequilibrium (LD): the nonrandom association of alleles at two or
more loci. LD has proven to be very useful in GWA studies where an allele at
one locus can be predicted by an allele at a second locus, thus removing the
need to genotype all loci.
Preprotachykinin 1 (TAC1): a gene that encodes a secreted neuropeptide called
substance P (SP). SP is expressed in dorsal root ganglia, where it controls
inflammatory pain, and in the amygdala, where it plays a role in modulating
mood
Post-translational modification: any modification of protein structure after
translation. Includes phosphorylation, glycosylation, and proteolysis. In the
case of transcription factors, post-translational modification is often mediated
by signal transduction cascades resulting in their increased or decreased ability
to bind DNA or modulate RNApolII activity.
Primary cell: an unmodified cell removed from a living animal and cultured
alive under laboratory conditions.
Promoter: a sequence of DNA next to the transcriptional start site of a gene that
acts as the initial binding site of RNApolII.
Signal transduction pathway: a cascade of specific protein modification events
in the cytoplasm that is often initiated by activation of cell surface receptors
and terminates in the post-translational modification of transcription factors in
the nucleus.
Silencer: a sequence of DNA that reduces the activity of a promoter region.
Single nucleotide polymorphism (SNP): the most common polymorphisms in
the genome generally affecting only one base pair to produce two or more
alleles at a particular locus.
Stratified medicine: the analysis of the genetic causes of differences in drug
response or disease susceptibility within populations.
Transfection: the process of introducing foreign DNA into single cells.
Transformed cell: a cell line that has undergone transformation to an
immortalized ‘cancer-like’ state.
Transcription factors (TF): proteins that bind cis-regulatory sequences follow-
ing their post-translational modification by signal transduction pathways. Once
bound, TFs can influence RNApolII activity as well as modulating chromatin
remodeling events.
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Figure 1. A highly simplified diagrammatic representation of a gene regulatory
system demonstrating the general flow of information within eukaryotic cells and
the points of interaction of cell signaling agonists and antagonists.
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100gene expression, have been found to influence expression
from a distance of 1 mega base (1 Mb) [17]. Recently, it has
been discovered that between 62% and 74% of the genome is
transcribed, including enhancers that generate transcripts
called eRNA [11]. The role of eRNA is unclear, but it has
been hypothesized that RNApolII, immobilized in nuclear
transcription factories, pulls on the genomeusing transcrip-
tion to manipulate enhancers and promoters into these
factories [18,19]. By contrast, silencers characteristically
downregulate gene expression by interacting with tran-
scription factors (TFs) called repressors that, in turn, recruit
corepressors to specifically modify histones and create a
closed chromatin structure, obstructing transcription [20].
Finally, insulator sequences protect gene promoters from
the regulatory influences controlling other genes [11].
Collectively, enhancers and silencers oftenwork together
to maintain the fine balance of tissue-specific promoter
activity appropriate for health [21]. Indeed, the coordinated
activity of many different enhancers and silencers may be
required to facilitate appropriate promoter responses to the
large number of information inputs received by the cell.
These responses are achieved through a combination of
forces: promoter binding by specific combinations of activat-
ed TFs or repressor proteins to regulate RNApolII activity
through a process that involves DNA looping, often over
many thousands of base pairs [22,23] (Figure 1). In vivo
observations in transgenic mice indicate that many CRSs
only function within very tight contextual limitations. For
example, the TAC1ECR1 element appears to only be active
in a subset of cells in the amygdala, a region of the brain that
controls fear behavior and may be involved in anxiety and
depression [24], and the GAL5.1 enhancer could only sup-
port expression in specific groups of cells in both the amyg-
dala and the hypothalamic paraventricular nucleus (PVN),
which controls dietary choice and alcohol intake [25]. The
proportion of cells in the human body in which these enhan-
cers are active is less than 0.001% of all cells. Nevertheless,
appropriate expression of the TAC1 andGALgenes in these
tissues is essential for health, a fact supported by the
extremely strong sequence conservation of ECR1 and
Box 1. High-throughput technologies for the analysis of genome wide cis-regulatory interactions
Large-scale genomic analysis exemplified by the ENCODE consortium
has been made possible by the development of next-generation
technologies that sequence a major proportion of the DNA molecules
in a given sample. In addition to producing sequence data, this
technology can quantify the relative amounts of any given sequence
within the DNA population. Techniques that use next-generation
sequencing technologies are given a -seq suffix. For example, RNA-
seq describes a technique for sequencing reverse-transcribed DNA
generated from an mRNA sample, which allows not only the
identification of the genes being expressed but also quantification
of their relative amounts.
FAIRE-seq. ‘Formaldehyde-assisted isolation of regulatory ele-
ments’ exploits the phenomenon that, following formaldehyde
treatment, transcriptionally ‘closed’ chromatin is relatively insoluble,
whereas DNA in a more open configuration (i.e., less associated with
histones) will remain more soluble and can be separated by phenol–
chloroform extraction [72]. Subsequent high-throughput sequencing
of DNA from the water-soluble fraction has been reported to provide
an accurate portrait of transcriptionally active regions within the
genome [72].
DNAse1 sensitivity mapping-seq (DNAse-seq). Although it does not
involve formaldehyde treatment, DNAse-seq is similar in concept to
FAIRE analysis in that it selectively breaks exposed, transcriptionally
active DNA. Briefly, cells are lysed to release their nuclei that are then
exposed to the DNAse1 enzyme, which is small enough to penetrate
deep into the chromatin and digest any exposed DNA [73]. DNA from
these nuclei is extracted and ligated to linker DNA that allows
recovery and analysis by next-generation sequencing.
5C [74] and Hi-C [75]. These technologies detect interactions
between widely separated sequences in the genome, such as remote
cis-regulatory elements and promoters, using formaldehyde cross-
linking. After formaldehyde crosslinking, chromatin is extracted from
cells and exposed to restriction endonucleases. Extracted chromatin
fragments are ligated at low concentrations and analyzed using next-
generation sequencing. In this way, a ‘snapshot’ of chromatin folding
in living cells and associations of widely separated parts of the
genome such as promoters and long-range enhancers can be
observed [76].
ChIP-seq (chromatin immunoprecipitation-seq). ChIP-seq analysis
detects the binding of specific TFs to genomic DNA within living cells
and starts with the formaldehyde treatment of cultured cells.
Chromatin is then extracted from these cells and sheared into
fragments by sonication. Enrichment of DNA fragments is carried
out using antisera raised against specific DNA binding proteins,
which also immunoprecipitates their bound DNA. The identity of this
bound DNA is analyzed using next-generation sequencing that also
determines relative quantities of immunoprecipitated DNA on a
genomic level [77–79].
Review Trends in Molecular Medicine February 2013, Vol. 19, No. 2GAL5.1 throughevolution. Thus, it is likely thatmanyCRSs
are only active if given the correct combination of signals
within the correct cell type, a phenomenon known as
context dependency. It therefore follows that in many
cases, the effects of polymorphisms on CRS activity will
only be revealed using paradigms that reflect this context
dependency. Understanding how regulatory polymor-
phisms influence context dependency will be the next
major step in understanding the basis of disease and drug
response stratification.
CRS and signal transduction relationships
Tissue-specific gene expression relies on the context-
dependent activity of CRSs. In turn, context dependency
relies on the relaying of contextual information, in the form
of specific types of cell–cell communication at the cell
surface (e.g., ligand–receptor interactions), to RNApolII
at gene promoters. Activation of cell surface receptors by
ligand binding subsequently activates signal transduction
cascades. Many hundreds of different ligand–receptor
interactions have been identified, and their effects on
the many different known signal transduction networks
have been widely published, which include the following
canonical examples: kinase A and C pathways [26,27], the
different mitogen activated protein kinase (MAPK) path-
ways (MEKK/ERK, p38 and JNK) [28], the JAK/STAT
pathways [29], the Wnt pathway [30], and the tyrosine
kinases [31], to name but a few. In addition to cell surface
proteins, nuclear receptors (NRs) act as both receptors and
TFs and form another layer of influence on gene regulation.
Examples of NRs include the sex hormone receptor, vita-
min D receptors, and stress hormone receptors (glucocor-
ticoid and mineralocorticoid receptors) [32].
The chain of events leading to the activation and/or
repression of RNApolII continues with the post-transla-
tional modification of TF proteins by activated signal
transduction pathways, leading to the phosphorylation,
glycosylation, or proteolytic digestion of TF proteins. Thisis a critical step in gene regulation, because a significant
majority of TFs need to be activated by signal transduction
pathways before they can bind CRSs, modify chromatin, or
influence RNApolII activity (Figure 1) [33]. Indeed, it is
now accepted that a major influence on disease suscepti-
bility and drug response stratification centers on polymor-
phisms within CRSs that alter interactions with TFs. A
vast literature describes the biochemistry and interactions
of signal transduction networks, and the protein–DNA
interactions that modulate gene expression. However, al-
most nothing is known about the effects of CRS polymor-
phisms on their ability to respond to signal transduction
cues. In the wake of the significant advances made by the
ENCODE consortium, filling this major knowledge gap is
the next critical step in understanding the mechanisms
through which CRS polymorphisms affect disease suscep-
tibility and drug response stratification.
Identifying a CRS
The main obstacle to understanding the mechanisms that
affectCRSactivityhasbeenour inability to identify them. In
the past, identifying CRSs has relied on the painstaking
deletion analysis of gene flanking regions. However, thanks
to the sequencing of the human genome and the availability
of evermore rapid advances in high-throughput sequencing
technologies, severalmore rapidandeffectivehigh-through-
put solutions have been devised to find and characterize
CRSs (summarized in Box 1 and Figure 2).
Thesemethods include formaldehyde-assisted identifica-
tion of regulatory elements and next generation sequencing
(FAIRE-seq) and DNAseI-seq analysis, which identify tran-
scriptionally active parts of the genome that are less tightly
associatedwithhistoneproteinsand soaremore susceptible
to mechanical and enzymatic fragmentation, respectively
[13,34]. A total of 2.9 million regions of the human genome
have been identified asDNAse1 hypersensitive sites (DHS),
vastly outnumbering known genes (23 000), and these are
indicative of active cis-regulatory regions [13]. At higher101
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Figure 2. A flow diagram describing the relationships between different technologies that can be used to identify and characterize cis-regulatory sequences (CRSs) and to
determine the effects of polymorphisms on their qualitative and quantitative activities using a series of different in vivo, in vitro, and high-throughput technologies. The first
row describes the technologies that can be used to identify CRSs (GWAS, genome-wide association analysis; ChIP-seq, chromatin immunoprecipitation sequencing; FAIRE-
seq, formaldehyde-assisted identification of regulatory element sequencing; 5C, carbon copy chromatin conformation capture). The second row describes the genome and
DNA manipulations required to test hypotheses relating to CRS activity and the effects of polymorphisms (SDM, site-directed mutation; Luc, luciferase; Lac, LacZ gene
encoding b-galactosidase; GFP, green fluorescent protein). The third row summarizes many of the different questions relevant to the understanding of the function of CRSs
and the effects of SNPs on their activity. The last row summarizes several different paradigms that can be used to address the questions posed in the third row (ES,
embryonic stem cell; QrtPCR, quantitative reverse transcriptase polymerase chain reaction; 3C, chromatin conformation capture; EMSA, electrophoretic mobility shift
assay; ChIP, chromatin immunoprecipitation). This flow diagram is not exhaustive and does not include technologies that allow analysis of epigenetic modification.
Review Trends in Molecular Medicine February 2013, Vol. 19, No. 2resolution, DNAse1 digestion within DHSs can indicate the
sites occupied by individual TFs – a technique known as
genomic DNAse1 footprinting [12]. Methods such as 5C and
Hi-C can identify interactions between different cis-regula-
tory elements at vast distances across the genome [22,35].
ChIP-seq is another technique that has been used by EN-
CODE to identify interactions between modified histones
and TFs throughout the genome [36]. The use of ChIP-seq
has identified a complex ‘chromatin signature’ based on the
occurrence of different methylation and acetylation states
for specific amino acids in different histones such as histone
3 (H3). For example, it has been shown that monomethyla-
tion of lysine 4 (K4) is a characteristic of H3 proteins that
associate with enhancer regions (H3K4Me1). Likewise, H3
with trimethylated K4 is associated with promoters
(H3K4Me3), and trimethylation of either H3 Lysine 27
or lysine 9 (H3K27Me3 and H3K9Me3, respectively) is
associated with silenced chromatin [37]. Other ChIP-seq102experiments have suggested that the binding of cofactors
such as p300 and mediator are indicative of enhancers [38].
The techniques described above represent levels of in-
vestment in technologies and expertise that only a few
specialized laboratories possess. An alternative to the ex-
perimental identification of cis-regulatory elements is the
use of in silico prediction based on information currently
available in online databases.One such in silico technique is
comparative genomics (Figure 2), which relies on the hy-
pothesis that sources of information in the genome impor-
tant for survival are conserved throughout evolution [39].
Using comparative genomics, it has been observed that
sequences that are deeply conserved – where depth of
conservation takes into account both evolutionary time
and sequence homology – such as that observed between
humans and fish (400 million years) often represent early
embryonic enhancer sequences [14,15,40]. However, these
embryonic enhancers are significantly less polymorphic,
Review Trends in Molecular Medicine February 2013, Vol. 19, No. 2thus reducing their usefulness in detecting the heritable
causes ofhumandisease [41]. Instead, amore fruitful search
for disease-causing regulatory polymorphisms may lie in
examining the conservation between less divergent gen-
omes such as birds and humans [25,42,43] or mice and
humans [21]. Initial findings from theENCODEconsortium
suggest that only 40%of conserved noncoding sequences are
functional [44], and these conclusions have somewhat re-
duced the perceived usefulness of comparative genomics in
the identification of CRSs. However, based on the evidence
of strong context dependency shown by many CRSs, it
cannot be ruled out that the functionality of much of the
remaining 60% of the conserved genome remains undetect-
ed because of the limitations of the cell culture-based para-
digms used by the early ENCODE project.
Paradigms for analyzing CRS function and signal
transduction response
The staggering amount of data generated by the ENCODE
consortium has been made publicly available through the
University ofCalifornia, SantaCruz (UCSC) genomebrows-
er (http://genome.ucsc.edu/index.html), ENSEMBL (http://
www.ensembl.org/index.html), and the ENCode project
website (http://encodeproject.org/ENCODE/). These repre-
sent one of the greatest platforms evermade available to the
scientific community [10]. However, the publication of this
resource represents only the very beginning of our under-
standing of the regulatory genome. The majority of the
conditions that affect the aging human population stem
from processes that arise later in life and have high degrees
of cell specificity. Because the vast majority of the CRSs
identified by the consortium have largely been described in
homogenous cell culture, a necessity for the genome-wide
high-throughput techniques used, it remains to be deter-
mined what proportion of the CRSs identified by ENCODE
possess the levels of context dependency required for appro-
priate cell-specific gene expression in vivo.
The ‘gold standard’ for determining the function of
predicted CRSs, or the effects of polymorphisms on their
activity, is analyzing the effect of their physical deletion
from the genome or reproducing specific disease-associated
alleles in living organisms. This is currently carried out
using embryonic stem (ES) cell targeting to produce what
are often referred to as ‘knockout’ mice. Mouse models are
living-four dimensional test beds that share many physio-
logical characteristics with humans. However, the use of
ES cell targeting in mice is time consuming, technically
challenging, and expensive (Figure 2) [45]. Therefore, be-
fore considering the production of CRS knockout models or
the reproduction of disease-associated alleles, exhaustive
in vivo (through pronuclear microinjection of DNA into
mouse 1 cell embryos as described later), cell-based, and in
vitro studies must be undertaken to identify and charac-
terize the most likely disease-causing polymorphic CRSs
and their degree of context dependency (Figure 2).
Promoter choice
CRSs are often unable to support the appropriate cell or
inducible gene expression in the absence of a promoter
region. Previously, CRS analyses have relied on the use of
‘generic’ or commercially available promoter sequencesthat have understandable advantages in terms of conve-
nience. Although many groups have used generic promo-
ters very successfully, observations of the requirement for
enhancer–promoter combinations have to be addressed in
the future, and this is best done using endogenous pro-
moters [42,46–48]. It is also important to note that the
ability of CRSs to upregulate or downregulate a given
promoter is often context dependent and varies depend-
ing on the cell types used to assay their activity, the
stimuli used, or the proximity of other regulatory
sequences [49,50]. The relationship between the ECR2
enhancer and the TAC1 promoter is a good example; the
ability of the TAC1 promoter to drive sensory neuron
specific expression, or to respond to MAP kinase path-
ways or noxious stimuli, depends on the remote enhancer
ECR2, which is itself inactive in the absence of the TAC1
promoter [42,51].
The alternative to using a generic ‘off the peg’ promoter is
to use endogenous promoters of genes of interest (Figure 2).
Following the same logic used to select remote CRSs,
comparative genomics, the extent of CpG islands, and
DNAse hypersensitivity mapping – information currently
available through the ENCode consortium – can determine
the extent of the endogenous promoter to be used [21,42,51].
Although cloning endogenous promoter regions to form
bespoke reporter constructs is time-consuming, there are
several clear and important advantages to their use:
1. Because an endogenous promoter maintains the
expression of its gene, it is easier to reconcile the
relevance of CRS effects on endogenous promoter
activity to the role of that CRS in controlling the
expression of the endogenous gene.2. Use of endogenous promoters addresses the question of
enhancer–promoter specificity [42,46,48].3. Use of an endogenous promoter allows for the analysis
of negative cis-regulatory regions whose importance in
gene regulation and health is emerging [21].Qualitative analysis The expression of many genes crucial
for health is often limited to a small number of specific cell
types in vivo. Therefore, candidate CRSs must be analyzed
to determine whether they are active within the same cell
types as the genes they are presumed to control. The most
cost-effective and rapid qualitative method of establishing
the tissue-specific activity of CRS sequences is by produc-
ing transgenic animals via pronuclear microinjection of
reporter gene constructs (Figure 2) [52]. The relevance of a
candidate CRS to the expression of the genes they regulate
is determined by colocalizing the expression of the reporter
gene products, such as GFP or LacZ, with the mRNA or
protein expressed from candidate genes (Figure 2). In
many cases, much of the cell-specific activity of isolated
human enhancer sequences analyzed using transgenic
mice have accurately reflected the expression of the homol-
ogous endogenous gene in mouse. For example, analysis of
the activity of the GAL5.1 enhancer, which lies 42 kb from
the galanin gene, using fluorescent immunohistochemistry
and in situ hybridization showed that expression of a LacZ
reporter linked to the GAL5.1 enhancer was active in cells
of the hypothalamic periventricular nucleus that also
expressed galanin mRNA and protein [25].103
Review Trends in Molecular Medicine February 2013, Vol. 19, No. 2Because of the random nature of transgene insertion,
transgenic analysis cannot easily be used to quantify dif-
ferences in the activity of polymorphic CRSs or the effects
of allelic variants on CRS response to signal transduction
cues [53]. Amuchmore accessible and reproduciblemethod
involves the quantitative analysis in relevant tissue or cell
cultures using reporter genes fused to generic or bespoke
gene promoters (Figure 2).
The types of cells previously used for reporter assays
include transformed cell lines such as COS and HeLa cells,
which can be readily grown in the laboratory and easily
transfected using standard protocols such as lipofection
(Figure 2) [54]. However, these immortalized cells have
undergone levels of phenotypic and genomic divergence
from their progenitor cells that present problems when
studying highly context-dependent CRSs. Primary cells
represent an alternative and arguablymore representative
paradigm of the endogenous cell types found in the body
and nervous system (Figure 2) [55]. Previous problems
associated with the refractory nature of primary neurons
to DNA transfection have been largely overcome using
systems such asAmaxa transfection [56] ormagnetofection
[57]. In keeping with previous observations [58], we have
found that the functional differences resulting from CRS
polymorphisms are often cell type dependent and best
assayed in several different primary cell types whose
identity reflects the known expression profile of the endog-
enous gene (Figure 2) [21,42,43,51].
Analyzing the effects of cis-regulatory variation on
signal transduction response
It has not been widely considered that a major source of
disease susceptibility and differences in drug efficacy may
result from polymorphism-induced changes in the ability of
CRSs to respond to signal transduction cues. Studies of the
effects of different gene polymorphisms on gene expression
in different regions of the brain have shown that the effects
of these SNPs vary significantly between regions [58].
These studies are supported by our own observations that
the effects of many SNPs within CRSs may not become
obvious until appropriate signal transduction cues are
present within the correct cell type [21]. Thus, given the
right context, the effects of allelic variation in CRSs can
often be significant in one cell type but not another. For
example, the major polymorphic variant of a highly con-
served CRS within intron 2 of the CNR1 (cannabinoid
receptor 1 gene) gene, which encodes the cannabinoid
receptor, was inactive in primary hippocampal neurons.
However, the minor variant, which was in strong LD with
another SNP associated with obesity and addictive behav-
ior, was highly active in hippocampal neurons and, in
contrast to the major variant, responded robustly to the
activation of MAP kinase pathways [43].
Exquisite balancing of tissue-specific gene expression
and response to very specific stimuli seems to be a property
of many genes that are essential to health. For example,
overexpression or underexpression of the brain-derived
neurotrophic factor (BDNF) gene produced similar depres-
sive symptoms in knockout or overexpressing mouse lines
and suggests that positive regulation of BDNF must be
balanced by negative regulatory influences [59,60]. One of104the best-studied BDNF promoters, BDNF prom IV, is
highly active in the amygdala, hippocampus, and cortex,
where it responds to stimuli such as cell depolarization and
the activation of PKC and Wnt signaling pathways. How-
ever, a polymorphic silencer element, BE5.2, containing an
SNP associated with depression (rs12273363) prevents
activation of BDNF prom IV by PKC and Wnt-signaling
pathways and only permits activation following cell depo-
larization or if both the PKC and PKA pathways are
simultaneously stimulated [21]. In this respect, BE5.2 acts
in a manner analogous to an ‘AND’ gate used in Boolean
algebra and computational design in its ability to ‘filter’ the
information contained in signal transduction cues. Signifi-
cantly, themood disorder associated C-allele of rs12273363
[61] increased the ability of BE5.2 to repress BDNF acti-
vation. Consistent with previous observations of region-
specific effects of SNPs on gene expression in the brain [58],
it has been observed that the C and T alleles of the BE5.2
silencer also behave differently in neurons derived from
the amygdala: in contrast to hypothalamic and cortical
neurons, the minor C-allele decreased the negative regu-
latory effects of BE5.2 on BDNF promoter IV [21].
Gene regulation, CRSs and epigenetics
In recent years, it has become evident that changes in
chromatin structure, which do not alter the primary se-
quence of the genome, induce phenotypic effects by altering
gene regulation. These processes have been referred to as
epigenetic modification and include chemical changes in
the methylation status of DNA at CpG sequences or meth-
ylation and acetylation of histone proteins that can be
inherited through many cell divisions and, purportedly,
between human generations [62]. Although the precise
mechanisms governing the heritability of these changes
are yet to be established, it is highly likely that epigenetic
modifications alter gene expression by changing the mode
of action of associated CRSs. For example, early life stress
resulted in hypomethylation of an enhancer that regulated
arginine vasopressin (AVP) expression in mice [63,64], and
hypomethylation of this AVP enhancer increased its activ-
ity, thus increasing expression of AVP in the PVN, an
expression profile associated with depression [63,64]. In-
triguingly, functional polymorphisms within the GAL5.1
and the CNR1 enhancer regions [25,43], which are candi-
dates for controlling the expression of the mood, appetite,
and painmodulating genes Galanin and cannabinoid recep-
tor 1, have introduced or removed novel CpG sequences,
respectively. Further examination of these loci using
genome-wide methylation analysis through the ENCODE
consortium web repository (http://genome.ucsc.edu/index.
html) showed that the CpGs involved were methylated in
these enhancers in cortical neurons, raising the possibility
that functional genetic variance may interact with epige-
netic modification to determine disease susceptibility (un-
published data). These observations are entirely consistent
with previous studies of allele-specific methylation [65].
Incorporation of GWA study data
In isolation, each of the techniques described above are
unlikely to identify the causes of disease or stratification. It
is essential that a multidisciplinary approach be used to
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and stratification as described in Figure 2. The first steps in
this processmust be informed fromGWA studies (Figure 2),
many of which have been compiled in databases such as the
HuGE navigator (http://hugenavigator.net/) or the NIH
GWAS catalog (http://www.genome.gov/gwastudies/). For
example, a few studies of critical diseases such as bipolar
disorder (BD) and type 2 diabetes (T2D) have returned
several GWA study hits that closely cluster and have shown
strong reproducibility in many different GWA studies. All
SNPs associated with BD and T2D are noncoding and
occur in intronic or intergenic sequence. In the case of
BD, multiple studies have identified noncoding SNPs
within the CACNA1c and ANK3 genes that demonstrate
strong associations with BD [66]. Tantalizingly, many of
these SNPs cluster within the third intron of the CAC-
NA1c gene and occurwithin a region in strongLD that also
includes several SNPs in highly conserved sequences. The
risk allele of one of these SNPs (rs1006737) increased
CACNA1C mRNA levels in patient lymphoblastoma cells
[67] and brain [68], suggesting a CRS effect. However, at
the time of writing, the authors were unaware of studies to
determine the mechanisms through which the rs1006737
risk allele affects susceptibility.
Other strong GWAS disease associations include that
between T2D and an SNP (rs7903146) within a repetitive
region within intron III of the human TCF7L2 gene [69].
Extensive comparative genomics and analysis of 92 kb of
TCF7L2 intron III in transgenic mouse embryos using an
exogenous heat shock promoter (Hsp68), succeeded in iden-
tifying multiple conserved regions that supported tissue-
specific expression in the bone primordia, nervous system,
andgut inembryonicday15.5mouseembryos [70].However,
determining the effects of the risk allele of rs7903146 on
cis-regulatory activity is still tobe achieved [70]. It is possible
that examining SNPs in LD with rs7903146 within con-
served regions using the endogenous TCF7L2 promoter in
primary cells may prove revealing. Intriguingly, the pro-
ducts of TCF7L2, the Wnt-pathway activated transcription
factor TCF4, demonstrate allele-specific binding to a cancer-
associated SNP (rs698327) within a remote CRS that con-
tacts and upregulates the activity of the c-MYC oncogene
locus, which is located 335 kb away [71]. These elegant
studies beautifully illustrate the efforts being made to rec-
oncile noncoding polymorphisms with disease.
In the case of both the CACNA1c and TCF7L2 genes, it
is clear that we have reached a critical stage where the
technologies described in the current manuscript, when
combined with the ENCODE consortium databases, will
make a real contribution to understanding the roles of BD
and T2D risk alleles in altering expression of these genes.
These examples demonstrate that we are currently on
the threshold of a major advance in our understanding
of the regulatorymechanisms governing the susceptibility
and progression of many diseases with a major heritable
component.
CRS polymorphisms and drug response stratification
The development and testing of novel pharmaceuticals is
all too often hampered by genetic heterogeneity, or strat-
ification, in Phase II and III human test cohorts thatgreatly reduces the significance of test data and delays
the delivery of novel compounds to the market. In addi-
tion, variations in the efficacy of, and side effects pro-
duced by, currently available drug therapies significantly
impacts on the ability of health services around the world
to deliver more effective personalized medicines. In order
to expedite future market delivery of drugs in an efficient
and timely manner, and to ensure the targeting of exist-
ing drugs to patients who would most benefit, the genetic
determinants that cause drug response stratification
must be identified. In addition to determining the causes
of disease, GWA studies have also been used to find the
causes of drug response stratification. Clues to the possi-
ble mechanisms through which polymorphisms in the
noncoding genome affect drug response can be seen in
the significant differences observed between the C and T
allele of the CNR1 ECR1 enhancer; the T allele responds
much more strongly to treatment using angiotensin II
[43]. GWAS-based approaches to determining the parts of
the genome responsible for response stratification include
the Genome-based Therapeutic Drugs for Depression
(GENDEP) study. The GENDEP consortium has used
GWAS analysis to determine the causes of nonresponse
to antidepressants and has identified several loci close to
or within the uronyl 2-sulfotransferase (UST) and protein
phosphatase 1A (PP1) genes that demonstrate strong
association with nonresponse to the antidepressants esci-
talopram and nortriptyline, respectively [6,8]. Again,
none of the SNPs associated with response occurred in
coding regions and, in common with disease-causing
SNPs, it is highly likely that the causes of escitalopram
and nortriptyline nonresponse are regulatory. Thus,
gaining a better understanding of the regulatory land-
scape surrounding the UST and PP1 genes will likely be
essential for understanding their role in drug response
stratification.
Concluding remarks
Thanks to the publication of the ENCODE consortium
findings and the results of hundreds of GWA study data
sets, there has never been a better time to understand how
regulatory polymorphisms affect the expression of genes
involved in disease susceptibility and drug response strat-
ification. An opportunity now exists to build on the achieve-
ments of the ENCODE consortium and examine how
disease-associated polymorphisms affect the activity of
CRSs using paradigms that accurately reflect their context
dependency. It will be interesting to determine how the
ENCODE data, recovered from human ES cells, HeLa
cells, or lymphoblastoma cells (human lymphocytes im-
mortalized using viruses) translates to the tight tissue-
specific expression of many genes in parts of the body such
as the hypothalamus or the amygdala, that control appe-
tite andmood, respectively, and where context dependency
can be at its most extreme. It is hoped that by combining
the ENCODE databases with the primary cell based and in
vivo techniques described above, a level of understanding
of the effects of SNPs or epigenetic modification in disease
susceptibility and drug response will soon emerge. Only in
this way will we be able to deliver on the promises of
stratified and personalized medicine.105
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